Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07036159

A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months

A Phase 2a, Open Label, Randomized, Interventional Study to Assess the Safety and Immunogenicity of Alternative Vaccination Regimens and Reduced Antigen Doses of RTS,S/AS01E Vaccine in Healthy Children Aged 5-60 Months in a Malaria-endemic Area

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
238 (estimated)
Sponsor
GlaxoSmithKline · Industry
Sex
All
Age
5 Months – 60 Months
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S/AS01E in healthy children aged 5-60 months in a malaria-endemic area.

Conditions

Interventions

TypeNameDescription
BIOLOGICALRTS,S/AS01E vaccineRTS,S/AS01E vaccine will be administered intramuscularly.

Timeline

Start date
2025-08-06
Primary completion
2027-04-23
Completion
2027-04-23
First posted
2025-06-25
Last updated
2025-09-29

Locations

2 sites across 1 country: Rwanda

Source: ClinicalTrials.gov record NCT07036159. Inclusion in this directory is not an endorsement.

A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months (NCT07036159) · Clinical Trials Directory